Fuse’s founding vision is to deliver lab quality diagnostic information wherever it is needed through innovative, rapid, low-cost tests.

As widely evidenced during the COVID-19 pandemic, current diagnostic approaches do not provide solutions that truly bridge the gap between laboratory-based and decentralised (point-of-need) tests. Low-cost tests suitable for use at the point-of-need, such as rapid antigen tests, do not have adequate performance whereas gold standard laboratory technologies require complex and expensive instrumentation.

Fuse was established in 2022 by the founders of Sense Biodetection Ltd. Under their leadership Sense raised c.$80m in investment and delivered the world’s first rapid instrument-free, molecular diagnostic test (Veros COVID-19). Sense was subsequently acquired by Sherlock Biosciences Inc.

Recognising that the first generation of molecular instrument-free product platforms do not meet the broader market requirements for point-of-need testing and that molecular technologies are only part of the puzzle, Fuse is leveraging its founders’ extensive experience and knowledge to develop a truly revolutionary new generation of multianalytic diagnostic products.

Fuse is backed by its founders’ strong network in the diagnostics industry built over 20 years, including renowned scientific, clinical and business leaders.